Thermo Fisher stock trades near consensus target as guidance supports outlook

Published on 09/06/2026 at 21:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Thermo Fisher stock is trading close to analysts' average target, with FY 2026 earnings guidance and a modest dividend yield shaping the risk-reward profile for investors.

Wissenschaftler arbeiten in modernem Biotech-Labor mit Analysegeräten und Probenbehältern — Fotorealistisches Laborbild zu Thermo Fisher Sci. US8835561023 zeigt moderne Analysegeräte und Wissenschaftler bei der Probenanalyse, Illustration mit AI erstellt.

Thermo Fisher Scientific stock (ISIN US8835561023) is quoted at 612.75 USD as of September 4, 2026 on the New York Stock Exchange, only slightly below the current analyst consensus target of 619.41 USD according to MarketBeat data published on September 6, 2026. This narrow gap between price and target makes the valuation a key point of attention for investors.

Guidance and consensus frame the earnings story

According to recent data compiled by MarketBeat, Thermo Fisher Scientific has set its fiscal year 2026 earnings guidance in a range of 24.930 to 25.330 USD per share. Research analysts currently expect earnings per share of 25.13 USD for the same period, which is positioned almost in the middle of the companys guidance range and signals a broadly aligned view between management and the market.

This guidance implies that, at the current share price of 612.75 USD as of September 4, 2026, the stock is trading at roughly 24 times the mid-point of the guided earnings range. For investors, the key comparison is that consensus EPS of 25.13 USD sits just 0.20 USD above the lower end of the guidance band and 0.20 USD below the upper end, underscoring how closely expectations track the companys official outlook.

Dividend remains small in the total return mix

The same MarketBeat overview reports that Thermo Fisher Scientific pays a quarterly dividend of 0.47 USD per share, with an announced payment scheduled for October 15, 2026 to shareholders of record on September 15, 2026. On an annualized basis this corresponds to 1.88 USD per share and, at the current share price of 612.75 USD, a dividend yield of about 0.3 percent.

With a reported dividend payout ratio of 10.11 percent of earnings, the company channels the vast majority of its income into reinvestment, acquisitions or share repurchases instead of cash distributions. For income-oriented investors, this low yield highlights that Thermo Fisher is positioned more as a growth and reinvestment story than as a high-yield defensive stock.

Go deeper

Thermo Fisher stock fundamentals and valuation

Read more Thermo Fisher coverage and see how earnings guidance, consensus expectations and dividend policy interact with the current share price.

More news on US8835561023 Investor Relations

Laboratory instruments underpin growth

Thermo Fisher Scientific generates a significant part of its revenue from laboratory instruments and consumables used in research, diagnostics and industrial quality control. One representative product segment is polymerase chain reaction, or PCR, instruments that enable precise DNA amplification for applications ranging from clinical diagnostics to genomics research.

The companys ProFlex PCR Systems line is a current example, offering flexible configurations such as dual 96 well and dual 384 well blocks to address high throughput sequencing and genotyping workflows, as described on the official product page updated in August 2025. In addition, a dual flat block supports Applied Biosystems OpenArray plate technology for high density genotyping on the QuantStudio 12K Flex Real Time PCR System, illustrating how Thermo Fisher integrates instrumentation with consumables and software in a broader workflow solution.

Stock price context for investors

With Thermo Fisher Scientific stock at 612.75 USD as of September 4, 2026 on the New York Stock Exchange, the companys equity value reflects strong earnings expectations but only a modest cash yield through dividends. The proximity of the current price to the average analyst target of 619.41 USD means that further upside in the near term will likely depend on the companys ability to deliver or exceed its earnings guidance range of 24.930 to 25.330 USD per share for fiscal year 2026.